Press room | News



Jul 30, 2015

Heptares Initiates Proprietary Therapeutic Antibody Program against a GPCR Target

Jun 25, 2015

Heptares StaR® Technology and its Impact on GPCR Drug R&D featured in New Report Celebrating UK Bioscience from the UK BioIndustry Association

Jun 17, 2015

Positive Outcome of Phase 1a Study with First-Ever Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Patients with Alzheimer's Disease

May 22, 2015

Heptares Scientist Wins Outstanding Young Chemist Award

Feb 23, 2015

Sosei Acquires Heptares Therapeutics for up to USD 400 million

Jan 23, 2015

Heptares Scientists To Receive The Malcolm Campbell Memorial Prize For 2015 In Recognition Of Their Outstanding Contribution To GPCR Drug Discovery

Jan 22, 2015

Heptares Technology Enables Breakthrough In Drug Discovery Collaboration With AstraZeneca

Jan 8, 2015

Heptares Adds Experts In Drug Discovery And Development To Its Board Of Directors

Back to top

Other News


© 2012-2015 Heptares Therapeutics